Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
$1.41
-0.20-12.42%
At close: -
$1.47
0.064.26%
After Hours: Apr 4, 6:50 PM EDT
Comments
Loading...
Prime Medicine Analyst Ratings and Price Targets | NASDAQ:PRME | Benzinga
Prime Medicine Inc has a consensus price target of $15.93 based on the ratings of 16 analysts. The high is $25 issued by Jefferies on November 14, 2022. The low is $10 issued by HC Wainwright & Co. on March 19, 2025. The 3 most-recent analyst ratings were released by Chardan Capital, HC Wainwright & Co., and Citizens Capital Markets on March 20, 2025, March 19, 2025, and March 4, 2025, respectively. With an average price target of $12 between Chardan Capital, HC Wainwright & Co., and Citizens Capital Markets, there's an implied 716.33% upside for Prime Medicine Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
Chardan Capital
HC Wainwright & Co.
Citizens Capital Markets
JMP Securities
Guggenheim
1calculated from analyst ratings
Analyst Ratings for Prime Medicine
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 03/20/2025 | Buy Now | 988.44% | Chardan Capital | Geulah Livshits44% | $15 → $16 | Maintains | Buy | Get Alert |
| 03/19/2025 | Buy Now | 580.27% | HC Wainwright & Co. | Arthur He35% | $10 → $10 | Reiterates | Buy → Buy | Get Alert |
| 03/04/2025 | Buy Now | 580.27% | Citizens Capital Markets | Silvan Tuerkcan44% | $10 → $10 | Reiterates | Market Outperform → Market Outperform | Get Alert |
| 03/03/2025 | Buy Now | 580.27% | HC Wainwright & Co. | Arthur He35% | $10 → $10 | Reiterates | Buy → Buy | Get Alert |
| 03/03/2025 | Buy Now | 920.41% | Chardan Capital | Geulah Livshits44% | $15 → $15 | Maintains | Buy | Get Alert |
| 12/10/2024 | Buy Now | 580.27% | JMP Securities | Silvan Tuerkcan44% | → $10 | Initiates | → Market Outperform | Get Alert |
| 12/03/2024 | Buy Now | 1124.49% | Guggenheim | Debjit Chattopadhyay50% | $18 → $18 | Reiterates | Buy → Buy | Get Alert |
| 11/13/2024 | Buy Now | 920.41% | Chardan Capital | Geulah Livshits44% | $17 → $15 | Maintains | Buy | Get Alert |
| 11/13/2024 | Buy Now | 580.27% | HC Wainwright & Co. | Arthur He35% | $10 → $10 | Reiterates | Buy → Buy | Get Alert |
| 10/25/2024 | Buy Now | 580.27% | HC Wainwright & Co. | Arthur He35% | $10 → $10 | Reiterates | Buy → Buy | Get Alert |
| 10/02/2024 | Buy Now | 580.27% | HC Wainwright & Co. | Arthur He35% | $10 → $10 | Reiterates | Buy → Buy | Get Alert |
| 08/09/2024 | Buy Now | 580.27% | HC Wainwright & Co. | Arthur He35% | $10 → $10 | Reiterates | Buy → Buy | Get Alert |
| 05/20/2024 | Buy Now | 580.27% | HC Wainwright & Co. | Arthur He35% | → $10 | Initiates | → Buy | Get Alert |
| 05/16/2024 | Buy Now | 580.27% | Citigroup | Samantha Semenkow33% | → $10 | Upgrade | Neutral → Buy | Get Alert |
| 05/13/2024 | Buy Now | 920.41% | JP Morgan | Eric Joseph43% | $16 → $15 | Maintains | Overweight | Get Alert |
| 05/07/2024 | Buy Now | 920.41% | Jefferies | Maury Raycroft31% | $23 → $15 | Assumes | Buy → Buy | Get Alert |
| 04/23/2024 | Buy Now | 716.33% | Wedbush | David Nierengarten60% | $12 → $12 | Reiterates | Outperform → Outperform | Get Alert |
| 04/22/2024 | Buy Now | 1056.46% | Chardan Capital | Geulah Livshits44% | → $17 | Initiates | → Buy | Get Alert |
| 04/08/2024 | Buy Now | — | TD Cowen | Joseph Thome34% | — | Initiates | → Buy | Get Alert |
| 04/03/2024 | Buy Now | 716.33% | Wedbush | David Nierengarten60% | → $12 | Initiates | → Outperform | Get Alert |
| 04/02/2024 | Buy Now | 716.33% | Wedbush | David Nierengarten60% | → $12 | Initiates | → Outperform | Get Alert |
| 03/08/2024 | Buy Now | 988.44% | JP Morgan | Eric Joseph43% | $26 → $16 | Maintains | Overweight | Get Alert |
| 03/05/2024 | Buy Now | 1260.54% | Guggenheim | Debjit Chattopadhyay50% | $24 → $20 | Maintains | Buy | Get Alert |
| 12/08/2023 | Buy Now | 580.27% | Citigroup | Samantha Semenkow33% | → $10 | Initiates | → Neutral | Get Alert |
| 11/07/2023 | Buy Now | 1668.71% | JP Morgan | Eric Joseph43% | $27 → $26 | Maintains | Overweight | Get Alert |
| 10/09/2023 | Buy Now | 1192.52% | BMO Capital | Kostas Biliouris32% | → $19 | Initiates | → Outperform | Get Alert |
| 09/06/2023 | Buy Now | 1260.54% | JonesTrading | Justin Walsh40% | → $20 | Initiates | → Buy | Get Alert |
| 08/14/2023 | Buy Now | 1192.52% | Morgan Stanley | Matthew Harrison61% | $21 → $19 | Maintains | Equal-Weight | Get Alert |
| 07/31/2023 | Buy Now | 1532.65% | Guggenheim | Debjit Chattopadhyay50% | → $24 | Initiates | → Buy | Get Alert |
| 04/18/2023 | Buy Now | 1124.49% | Stifel | Dae Gon Ha48% | → $18 | Initiates | → Buy | Get Alert |
| 01/24/2023 | Buy Now | 1328.57% | Morgan Stanley | Matthew Harrison61% | $23 → $21 | Maintains | Equal-Weight | Get Alert |
| 11/14/2022 | Buy Now | 1736.73% | JP Morgan | Eric Joseph43% | → $27 | Initiates | → Overweight | Get Alert |
| 11/14/2022 | Buy Now | 1600.68% | Jefferies | Eun Yang34% | → $25 | Initiates | → Buy | Get Alert |
| 11/14/2022 | Buy Now | 1464.63% | Morgan Stanley | Matthew Harrison61% | → $23 | Initiates | → Equal-Weight | Get Alert |
| 11/14/2022 | Buy Now | 1396.6% | Goldman Sachs | Salveen Richter51% | → $22 | Initiates | → Neutral | Get Alert |
FAQ
What is the target price for Prime Medicine (PRME) stock?
The latest price target for Prime Medicine (NASDAQ:PRME) was reported by Chardan Capital on March 20, 2025. The analyst firm set a price target for $16.00 expecting PRME to rise to within 12 months (a possible 988.44% upside). 19 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Prime Medicine (PRME)?
The latest analyst rating for Prime Medicine (NASDAQ:PRME) was provided by Chardan Capital, and Prime Medicine maintained their buy rating.
When was the last upgrade for Prime Medicine (PRME)?
The last upgrade for Prime Medicine Inc happened on May 16, 2024 when Citigroup raised their price target to $10. Citigroup previously had a neutral for Prime Medicine Inc.
When was the last downgrade for Prime Medicine (PRME)?
There is no last downgrade for Prime Medicine.
When is the next analyst rating going to be posted or updated for Prime Medicine (PRME)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Prime Medicine, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Prime Medicine was filed on March 20, 2025 so you should expect the next rating to be made available sometime around March 20, 2026.
Is the Analyst Rating Prime Medicine (PRME) correct?
While ratings are subjective and will change, the latest Prime Medicine (PRME) rating was a maintained with a price target of $15.00 to $16.00. The current price Prime Medicine (PRME) is trading at is $1.47, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.